Momo Medical vs Superluminal Medicines
Side-by-side comparison of AI visibility scores, market position, and capabilities
AI bed sensor system for nursing homes preventing pressure ulcers with 30% care efficiency improvement; $8.89M Series A from PGGM serving 250 facilities across Netherlands, Germany, and US.
About
Momo Medical is a medical technology company developing AI-powered bed sensor systems for nursing homes that monitor patient position and mobility — detecting when nursing home residents have been in the same position for too long (increasing pressure ulcer risk) and alerting care staff with optimal repositioning recommendations, making nursing care more proactive and efficient. Founded in the Netherlands and backed by Y Combinator, Momo Medical raised $9 million total including an $8.89 million Series A led by PGGM (a Dutch pension fund manager) in August 2024.\n\nMomo Medical's under-mattress sensor pad continuously monitors patient position without requiring wearables or cameras, providing pressure distribution data and movement detection that feeds into an AI system. The system learns each patient's typical movement patterns and identifies deviations that may indicate clinical concerns. For nursing staff, Momo provides a dashboard showing all patients' positioning status, flagging who needs repositioning, and eliminating the need for manual turn schedules (which are often missed during busy shifts). The company claims a 30% improvement in nursing staff effectiveness through reduction of unnecessary rounds and better-timed interventions.\n\nIn 2025, Momo Medical serves 250 nursing home locations across the Netherlands, Germany, Canada, and the United States, with 246% revenue growth in 2023 demonstrating strong market pull. The company competes in the elder care monitoring space with EarlySense (bed sensor for acute care), Oxevision (optical monitoring), and various wearable patient monitoring solutions for nursing home safety and care efficiency. Pressure ulcers are one of the most prevalent and preventable nursing home complications, costing healthcare systems billions annually. The PGGM backing is strategically significant — PGGM manages pension funds for Dutch healthcare workers, creating a natural distribution channel through the Dutch healthcare system. The 2025 strategy focuses on scaling across more European nursing home networks and growing the North American presence.
Boston AI GPCR drug discovery with $1.3B Eli Lilly collaboration Aug 2025 for obesity/cardiometabolic; $158M total ($120M RA Capital/Insight/NVIDIA/Lilly Series A Sep 2024) with MC4R obesity program advancing to IND competing with Relay Therapeutics.
About
Superluminal Medicines is a Boston-based biotechnology company — backed with approximately $158 million in total funding including a $33 million seed in 2023 and a $120 million Series A in September 2024 led by RA Capital Management with Insight Partners, NVIDIA's NVentures, and Eli Lilly — developing AI-driven small molecule drugs targeting G protein-coupled receptors (GPCRs), combining artificial intelligence, protein dynamics simulation, and structural biology to discover drugs for 70% of GPCRs that currently remain "undruggable" despite GPCRs representing the target class for approximately 35% of all FDA-approved drugs. In August 2025, Superluminal secured a landmark $1.3 billion collaboration agreement with Eli Lilly to discover small molecule therapeutics for obesity and cardiometabolic diseases, and is advancing its lead internal MC4R agonist program (for obesity treatment) toward IND-enabling studies with human trials expected Q4 2026. Founded in 2022.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.